mevalonic acid has been researched along with Osteoporosis in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (80.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chin, KY; Ghafar, NA; Hasan, WNW; Jolly, JJ; Soelaiman, IN | 1 |
| Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Li, M; Liu, YJ; Shao, C; Wang, C; Yue, H; Zhang, H; Zhang, ZL; Zheng, H | 1 |
| Hanayama, R; Kunugiza, Y; Makino, H; Morishita, R; Nakagami, H; Osako, MK; Rakugi, H; Shimizu, H; Tomita, T; Tsukamoto, I; Yoshikawa, H | 1 |
| Aoyama, K; Kimoto, A; Minamide, T; Miyata, K; Mori, H; Mori, M; Nozaki, K; Sasamata, M; Shimizu, K; Shimokawa, K; Suzuki, H; Tanaka, M; Usui, T; Yamamotoya, H | 1 |
| Capecchi, PL; Capperucci, C; Ferrata, P; Frediani, B; Galeazzi, M; Laghi-Pasini, F; Lazzerini, PE; Niccolini, S; Spreafico, A | 1 |
| Komatsu, S; Ohta, T; Tokutake, N | 1 |
| Reszka, AA; Rodan, GA | 1 |
| Ishimi, Y | 1 |
| Taguchi, M; Takeuchi, Y | 1 |
| Russell, RG | 1 |
| Inaba, M; Nishizawa, Y; Yamada, S | 1 |
| Abe, K; Asami, S; Kodama, T; Konishi, K; Oikawa, S; Sugiyama, M | 1 |
| Mundy, GR | 1 |
| Yoneda, T | 1 |
| Cruz, AC; Gruber, BL | 1 |
11 review(s) available for mevalonic acid and Osteoporosis
| Article | Year |
|---|---|
Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Drug Development; Drug Discovery; Humans; Mevalonic Acid; Molecular Targeted Therapy; Osteoporosis; Protein Prenylation; Signal Transduction | 2018 |
Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Geranyltranstransferase; GTP-Binding Proteins; Humans; Imidazoles; Mevalonic Acid; Osteoporosis; Spinal Fractures | 2009 |
[Pharmacological and clinical properties of alendronate sodium hydrate].
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clinical Trials as Topic; Depression, Chemical; Fractures, Bone; GTP-Binding Proteins; Humans; Mevalonic Acid; Osteoclasts; Osteoporosis; Protein Prenylation | 2002 |
Bisphosphonate mechanism of action.
Topics: Apoptosis; Bone Resorption; Diphosphonates; Humans; Mevalonic Acid; Osteoclasts; Osteoporosis | 2003 |
[The role of mevalonate pathway in osteogenic cells].
Topics: Acyl Coenzyme A; Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Bone Resorption; Cell Differentiation; Diphosphonates; Fractures, Bone; GTP-Binding Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Polyisoprenyl Phosphates; Protein Prenylation; Sesquiterpenes; Signal Transduction; Transforming Growth Factor beta | 2004 |
[Anabolic effects of statin and beta-blocker on bone metabolism].
Topics: Adrenergic beta-Antagonists; Animals; Bone and Bones; Bone Density; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Risk; Stimulation, Chemical; Sympathetic Nervous System | 2004 |
Bisphosphonates: from bench to bedside.
Topics: Bone Density Conservation Agents; Humans; Mevalonic Acid; Organophosphonates; Osteitis Deformans; Osteoporosis | 2006 |
[Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
Topics: Alendronate; Apolipoprotein A-I; Arthritis, Rheumatoid; Atherosclerosis; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cholesterol, HDL; Humans; Mevalonic Acid; Osteoporosis | 2007 |
Statins and their potential for osteoporosis.
Topics: Diphosphonates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Osteoblasts; Osteoporosis | 2001 |
[Stimulation of bone formation by anti-hyperlipidemic agent statins and its mechanism of action].
Topics: Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lovastatin; Mevalonic Acid; Osteogenesis; Osteoporosis; Stimulation, Chemical; Transforming Growth Factor beta | 2002 |
Statins and osteoporosis: can these lipid-lowering drugs also bolster bones?
Topics: Animals; Bone Density; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Female; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Osteogenesis; Osteoporosis; Transforming Growth Factor beta | 2002 |
4 other study(ies) available for mevalonic acid and Osteoporosis
| Article | Year |
|---|---|
Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.
Topics: Aged; Alendronate; Alleles; Asian People; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Haplotypes; Humans; Lumbar Vertebrae; Mevalonic Acid; Osteoporosis; Phosphotransferases (Alcohol Group Acceptor); Polymorphism, Single Nucleotide; Postmenopause | 2015 |
Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action.
Topics: Animals; Animals, Newborn; Antioxidants; Cell Differentiation; Cells, Cultured; Diet; Down-Regulation; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Female; Fluvastatin; Fructose; Indoles; Insulin Resistance; Mevalonic Acid; Osteoclasts; Osteoporosis; Rabbits; Rats; Rats, Wistar; Signal Transduction | 2009 |
Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells.
Topics: Aged; Bone Resorption; Cell Proliferation; Cell Survival; Cells, Cultured; Culture Media; Diterpenes; Farnesol; Femur Head; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Interleukin-6; Mevalonic Acid; Middle Aged; Osteoblasts; Osteoporosis; Osteoprotegerin; Pyrimidines; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Terpenes | 2013 |
Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells.
Topics: Anti-Bacterial Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Cloning, Molecular; Disulfides; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Indole Alkaloids; Lovastatin; Mevalonic Acid; Osteoporosis; Osteosarcoma; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured | 2000 |